Treatment	treatment	O	O	O	O
of	of	O	O	O	O
Crohn	crohn	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
with	with	O	O	O	O
fusidic	fusidic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
:	:	O	O	O	O
an	an	O	O	O	O
antibiotic	antibiotic	O	O	O	O
with	with	O	O	O	O
immunosuppressive	immunosuppressive	O	O	O	O
properties	properties	O	O	O	O
similar	similar	O	O	O	O
to	to	O	O	O	O
cyclosporin	cyclosporin	O	O	OTHERS	I
.	.	O	O	O	O

Fusidic	fusidic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
an	an	O	O	O	O
antibiotic	antibiotic	O	O	O	O
with	with	O	O	O	O
T-cell	t-cell	O	O	O	O
specific	specific	O	O	O	O
immunosuppressive	immunosuppressive	O	O	O	O
effects	effects	O	O	O	O
similar	similar	O	O	O	O
to	to	O	O	O	O
those	those	O	O	O	O
of	of	O	O	O	O
cyclosporin	cyclosporin	O	O	OTHERS	I
.	.	O	O	O	O

Because	because	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
need	need	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
new	new	O	O	O	O
treatments	treatments	O	O	O	O
for	for	O	O	O	O
Crohn	crohn	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
pilot	pilot	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
undertaken	undertaken	O	O	O	O
to	to	O	O	O	O
estimate	estimate	O	O	O	O
the	the	O	O	O	O
pharmacodynamics	pharmacodynamics	O	O	O	O
and	and	O	O	O	O
tolerability	tolerability	O	O	O	O
of	of	O	O	O	O
fusidic	fusidic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
in	in	O	O	O	O
chronic	chronic	O	O	O	O
active	active	O	O	O	O
,	,	O	O	O	O
therapy-resistant	therapy-resistant	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Eight	eight	O	O	O	O
Crohn	crohn	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
were	were	O	O	O	O
included	included	O	O	O	O
.	.	O	O	O	O

Fusidic	fusidic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
administered	administered	O	O	O	O
orally	orally	O	O	O	O
in	in	O	O	O	O
a	a	O	O	O	O
dose	dose	O	O	O	O
of	of	O	O	O	O
500	500	O	O	O	O
mg	mg	O	O	OTHERS	I
t.d.s	t.d.s	O	O	O	O
.	.	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
was	was	O	O	O	O
planned	planned	O	O	O	O
to	to	O	O	O	O
last	last	O	O	O	O
8	8	O	O	O	O
weeks	weeks	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
disease	disease	O	O	O	O
activity	activity	O	O	O	O
was	was	O	O	O	O
primarily	primarily	O	O	O	O
measured	measured	O	O	O	O
by	by	O	O	O	O
a	a	O	O	O	O
modified	modified	O	O	O	O
individual	individual	O	O	O	O
grading	grading	O	O	O	O
score	score	O	O	O	O
.	.	O	O	O	O

Five	five	O	O	O	O
of	of	O	O	O	O
8	8	O	O	O	O
patients	patients	O	O	O	O
(	(	O	O	O	O
63	63	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
improved	improved	O	O	O	O
during	during	O	O	O	O
fusidic	fusidic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
:	:	O	O	O	O
3	3	O	O	O	O
at	at	O	O	O	O
two	two	O	O	O	O
weeks	weeks	O	O	O	O
and	and	O	O	O	O
2	2	O	O	O	O
after	after	O	O	O	O
four	four	O	O	O	O
weeks	weeks	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
were	were	O	O	O	O
no	no	O	O	O	O
serious	serious	O	O	O	O
clinical	clinical	O	O	O	O
side	side	O	O	O	O
effects	effects	O	O	O	O
,	,	O	O	O	O
but	but	O	O	O	O
dose	dose	O	O	O	O
reduction	reduction	O	O	O	O
was	was	O	O	O	O
required	required	O	O	O	O
in	in	O	O	O	O
two	two	O	O	O	O
patients	patients	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Biochemically	biochemically	O	O	O	O
,	,	O	O	O	O
an	an	O	O	O	O
increase	increase	O	O	O	O
in	in	O	O	O	O
alkaline	alkaline	O	O	O	O
phosphatases	phosphatases	O	O	O	O
was	was	O	O	O	O
noted	noted	O	O	O	O
in	in	O	O	O	O
5	5	O	O	O	O
of	of	O	O	O	O
8	8	O	O	O	O
cases	cases	O	O	O	O
(	(	O	O	O	O
63	63	O	O	O	O
%	%	O	O	O	O
)	)	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
greatest	greatest	O	O	O	O
increases	increases	O	O	O	O
were	were	O	O	O	O
seen	seen	O	O	O	O
in	in	O	O	O	O
those	those	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
elevated	elevated	O	O	O	O
levels	levels	O	O	O	O
prior	prior	O	O	O	O
to	to	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
reversed	reversed	O	O	O	O
to	to	O	O	O	O
pre-treatment	pre-treatment	O	O	O	O
levels	levels	O	O	O	O
after	after	O	O	O	O
cessation	cessation	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
pilot	pilot	O	O	O	O
study	study	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
fusidic	fusidic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
may	may	O	O	O	O
be	be	O	O	O	O
of	of	O	O	O	O
benefit	benefit	O	O	O	O
in	in	O	O	O	O
selected	selected	O	O	O	O
chronic	chronic	O	O	O	O
active	active	O	O	O	O
Crohn	crohn	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
in	in	O	O	O	O
whom	whom	O	O	O	O
conventional	conventional	O	O	O	O
treatment	treatment	O	O	O	O
is	is	O	O	O	O
ineffective	ineffective	O	O	O	O
.	.	O	O	O	O

Because	because	O	O	O	O
there	there	O	O	O	O
seems	seems	O	O	O	O
to	to	O	O	O	O
exist	exist	O	O	O	O
a	a	O	O	O	O
scientific	scientific	O	O	O	O
rationale	rationale	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
fusidic	fusidic	CHEMICALS	O	OTHERS	I
acid	acid	CHEMICALS	O	OTHERS	I
at	at	O	O	O	O
the	the	O	O	O	O
cytokine	cytokine	O	O	O	O
level	level	O	O	O	O
in	in	O	O	O	O
inflammatory	inflammatory	O	O	OTHERS	I
bowel	bowel	O	O	OTHERS	I
disease	disease	O	O	OTHERS	I
,	,	O	O	O	O
we	we	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
role	role	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
treatment	treatment	O	O	O	O
should	should	O	O	O	O
be	be	O	O	O	O
further	further	O	O	O	O
investigated	investigated	O	O	O	O
.	.	O	O	O	O

